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Summary
Background Dendritic cells (DC) mediate inflammation in rodent models of allergic airway
disease, but the role played by human respiratory-tract DC (hRTDC) in atopic asthma remains
poorly defined. Recent data suggest that CD1 antigen presentation by hRTDC may contribute
to asthma pathogenesis.
Objective To investigate the influence of hRTDC on the balance between atopy and allergic
asthma in human subjects and to determine whether CD1 expression by hRTDC is modulated
during asthmatic inflammation.
Methods Sputum cells were induced from steroid-naı¨ve, allergen-challenged and allergen-
naı¨ve subjects (atopic asthmatics, atopic non-asthmatics and non-atopic controls). hRTDC
were identified using monoclonal antibody labelling and analysis by flow cytometry.
Results hRTDC stained HLA-DR1 (negative for markers of other cell lineages) were
predominantly myeloid and comprised 0.5% of viable sputum cells. Sputum cells were
potent stimulators of allogeneic CD41 naı¨ve T cells and enrichment/depletion experiments
correlated stimulatory potency with DC numbers. Sputum contained cells that exhibited
typical dendritic morphology when analysed by electron microscopy. Myeloid hRTDC were
endocytically active, but uptake of FITC-dextran was enhanced in cells from asthmatics
(Po 0.001). Despite their increased endocytic capacity, asthmatic myeloid hRTDC appeared
mature and expressed increased levels of maturation markers (Po 0.05–Po 0.001), CD1c,
CD1d and langerin (Po 0.05). CD1c expression by asthmatic myeloid hRTDC was enhanced
upon in vivo allergen challenge (three to ninefold within 24 h; Po 0.05). CD11cCD123high
hRTDC were only detected in asthmatic sputum and were increased in number following
allergen challenge.
Conclusion Despite limited cell numbers, it proved possible to analyse human RTDC in
induced sputum, providing evidence that increased antigen uptake and enhanced CD1
presentation by activated hRTDC may contribute to allergic airway disease. CD1 presentation
by hRTDC in atopic asthma may therefore constitute a novel target for future intervention
strategies.
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Introduction
Allergic asthma is characterized by chronic eosinophilic
inflammation and reversible obstruction of the airways
[1]. While up to 50% of the western population is
sensitized to allergens, only 7–10% of adults exhibit
symptoms of asthma [2]. Additional factors are evidently
required to confer asthmatic disease.
Dendritic cells (DC) are the most potent known activa-
tors of naı¨ve T cells [3]. DC present peptide–MHC com-
plexes to T cell subsets, but can also present antigens
in the context of CD1, a family of molecules that
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incorporates multiple different isoforms (CD1a, CD1b,
CD1c and CD1d) [4 – 6]. DC mediate the immune response
to inhaled allergens and are thought to play a critical role
in asthma pathogenesis [7], but detailed analyses of
respiratory-tract DC (RTDC) are currently limited to stu-
dies in animal systems. Recent data suggest that CD1
antigen presentation by human respiratory-tract dendritic
cells (hRTDC) may contribute to asthma pathogenesis [8].
Indeed, in the case of phospholipid antigens extracted
from pollen, CD1a and CD1d expressed by monocyte-
derived DC are involved in antigen binding and presenta-
tion to a number of different ab and gd T cell subsets,
including natural killer T cells (NKT cells) [9]. These
observations lead to the hypothesis that hRTDC expression
of CD1 molecules is altered in asthma and contributes to
disease pathogenesis by stimulating CD1-restricted lym-
phocytes (such as NKT cells) in the pulmonary tissues [10].
However, it is currently unknown whether CD1 expression
by RTDC is modulated in the asthmatic human lung.
In murine models, altering the balance of DC subsets in
the lung is sufficient to induce pulmonary eosinophilia
[11], while under non-inflammatory conditions, DC can
produce regulatory cytokines and mediate allergen toler-
ance [12]. However, the extent to which data from mouse
models of asthma can be extrapolated to the human
disease remains unclear [13], and a number of key points
arising frommurine models remain untested in the human
system.
DC are known to reside in the asthmatic lung and
increase in number following allergen challenge [14].
However, many early studies of hRTDC used isolation
protocols that incorporated culture steps that we now
recognize induce phenotypic and functional changes in
DC [15, 16]. We have developed a non-invasive approach
to the analysis of hRTDC in induced sputum that limits
ex vivo manipulation, thereby minimizing inadvertent
effects upon DC phenotype. Multi-parameter analysis
of unmanipulated hRTDC by flow cytometry allows
unambiguous identification of DC subsets and quanti-
tative analysis of their phenotype that has not previously
been possible using only histological approaches. Indeed,
detailed characterization of the predominant DC subset in
murine lung has only recently been reported [17], and
comparable data for the human airways are not yet
available.
Using a novel, multi-parameter approach, we aimed to
investigate the influence of hRTDC on the balance be-
tween atopy and allergic asthma in human subjects and to
determine whether CD1 expression by hRTDC is modu-
lated during asthmatic inflammation. Here, we report the
successful characterization of the trace DC populations
present in sputum from human subjects and identify
changes in DC activation, antigen uptake and expression
of CD1c and CD1d that are specifically associated with
atopic asthma. Furthermore, we demonstrate that hRTDC
expression of co-stimulatory molecules and CD1c anti-
gen-presenting molecules is modulated upon allergen
inhalation. These findings support a critical role for
CD11 human RTDC in the pathogenesis of allergic asthma.
Methods
Subjects
Sputum donors (non–atopic control = 12, atopic-asth-
matic = 15, atopic non-asthmatic = 6) were light/non-
smokers. Smoking was prohibited for X1 year preceding
the study, steroids excluded for X1 month prior and
antihistamines precluded for X24 h before induction.
Volunteers were in good general health and free from
respiratory infection for X1 month before taking part.
Written, informed consent was obtained from all partici-
pants. The study was approved by the Harrow Research
Ethics Committee.
Spirometry
Lung function was measured using routine spirometry
(Vitalograph, Bucks or Jaeger-Masterscope, Wurzberg,
Germany). Asthmatic subjects presented with mild, rever-
sible airway obstruction and a clinical history of asthma
(Table 1).
Skin-prick testing
D. pteronyssinus, dog, cat, feathers, grass pollen,
C. herbarum, A. alternata, C. albicans, and A. fumigatus
(ALK-Abello´, Hrsholm). Atopic donors displayed positive
reactions to X2 aeroallergens or exhibited an atopic
family history and 1 positive reaction.
Allergen challenge
The allergen challenge procedure was modified from
published guidelines [18]. Asthmatic subjects who exhib-
ited a forced expiratory volume in 1 s (FEV1)4 70% of
predicted values, a positive skin test to Der p 1 and/or Fel d
1 and methacholine PC20 o 8mg/mL were challenged
with the corresponding allergen (Aquagen SQ, 250 –
64 000 U/mL; ALK-Abello´). Subjects inhaled five breaths
of normal saline (0.9%) from a dosimeter (Mefar, Brescia,
Italy) and gave two consistent measurements of FEV1 at 5
and 10min post-saline inhalation. Allergen was adminis-
tered in the same way as the saline with FEV1 measure-
ments being taken at 5min intervals. Where FEV1 fell
o 15% from post-saline baseline, the allergen dose was
doubled. Where FEV1 declined 15–20% from post-saline
baseline, the allergen dose was unchanged. The challenge
procedure continued until a X20% decline in FEV1 was
achieved.
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Sputum induction
Sputum induction and processing were consistent with
published guidelines [19]. Volunteers were pre-treated
with 200 mg inhaled salbutamol 15min before induction.
Donors inhaled nebulized saline (4.5%) for 1min before
giving two consistent measurements of FEV1. Saline was
administered via DeVilbiss/Medel (De Vilbiss-Sunrise
Medical, Wollaston, UK; Medel–White Medical, Rugby,
UK) ultrasonic nebulizers for a maximum of 20min or
until FEV1 fellX20% from post-bronchodilator baseline.
Interruptions occurred at 5 min intervals for measurement
of FEV1 or as sputum was produced. Fluid from the buccal
cavity was expectorated into a petri-dish and the mucus
plugs selected out.
Sputum processing
Mucus plugs were weighed and digested in a fourfold
quantity of 0.1% v/v dithiothreitol (Calbiochem, San
Diego, CA, USA). The digestion mixture was incubated at
37 1C for 20min and then diluted 1:1 with PBS. The
resultant cell suspension was filtered through 48 mm
gauze and centrifuged (650 g, 4 1C, 10min). The super-
natant was discarded and the cells were re-suspended in
PBS.
Antibody labelling
Sputum cells were labelled with mAb on ice for 20min;
anti-CD1d (clone CD1d42), b7 Integrin (FIB504), CD80
(L307.4), CD83(HB15e), CD123(9F5), CD34(581) and HLA-
DR(G46-6) were from BD Biosciences (Cardiff, UK). Anti-
CD3(UCHT1), CD14(RMO52), CD16(3G8), CD19(J4.119),
CD124(S456C9), langerin(DCGM4) and CD56(N901) were
from Beckman Coulter (High Wycombe, UK). Anti-CD1a
(NA1/34), CD40(LOB7/6) and CD86(BU63) were from Ser-
otec (Oxford, UK). Anti-CD1c(AD5-8E7) and BDCA-
3(AD5-14H12) were from Miltenyi Biotec (Bisley, UK).
Anti-DC-SIGN(120507) was from R&D Systems (Abing-
don, UK) and anti-CD11c(KB90) was from Dako Cytoma-
tion (Ely, UK). Corresponding isotype-matched controls
were purchased from the respective manufacturers. Non-
specific binding was blocked by addition of fetal calf
serum (FCS) before labelling. The labelled cells were
washed in FACS buffer (PBS, 2% FCS, 0.02% sodium
azide, 1mM EDTA) and centrifuged (500 g, 4 1C, 5min).
The supernatants were discarded, and the cell pellets fixed
in 1% paraformaldehyde.
Flow cytometry
Data acquisition was by a FACSCalibur flow cytometer
(Becton Dickinson, Oxford, UK), and analysis using Win-
List software (Verity, Maine). Live cells were analysed on a
plot of HLA-DR vs. lineage cocktail staining (lin; mAb
labels for CD3, CD14, CD16, CD19, CD34 and CD56
against unwanted cell lineages). DC were identified as
HLA-DR1lin /dim cells. The proportion of label1 cells was
measured by gating on events that exceeded the fluores-
cence range of the isotype control. Enhanced normalized
subtraction was used to measure the staining intensity of
the positive cells (expressed as the positive intensity/PI
ratio relative to the isotype control).
Endocytosis assay
Sputum cells in complete medium (Dutch-modified RPMI-
1640, 10% FCS, 100 mM/Lu penicillin, 100 mgmml 1 strep-
tomycin, 20mM L-glutamine) were incubated at 4 1C or
37 1C ml1 with or without 1mg/mL FITC-dextran for 15,
30, 45 or 60min. Endocytosis was halted by addition of
ice-cold FACS buffer after incubation. Sputum cells were
washed in FACS buffer (5min, 500 g, 4 1C), labelled with
mAb on ice for 20min, washed and fixed. Sputum macro-
phages (autofluorescent CD141CD16dim/linbrightHLA-DR1
cells) were analysed alongside hRTDC as an endocytosis
positive control. FITC staining at 4 1C was subtracted from
that measured at 37 1C to obtain net mean fluorescence
intensity.
Table 1. Subject demographics
Age FEV1 %Pred
 %Improvew FEV1/FVC%
z %Eos‰
Asthma; Mean 35 88.51 9.62 78.46 3.86
Range 21–67 53.8–115 0–29.73 50–96.8 0.4–18.8
Control; Mean 32 100.36 1.97 84.63 0.1
Range 21–57 83.7–115 0–6.3 74.3–99 0–0.2
Atopic; Mean 42 108.6 0.44 84.55 0.16
Range 22–61 85.3–123.6 0–1.4 70.5–92.1 0–0.6
FEV1 as a function of predicted values (adjusted for age, sex, weight and ethnicity).
wPost-bronchodilator improvement in FEV1.
zFEV1/FVC ratio.
‰Sputum eosinophilia as assessed by differential counting.
FEV1, forced expiratory volume in 1 s, FVC, forced vital capacity.
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Mixed leucocyte reaction (MLR)
Human whole blood was diluted 2:1 with Dutch-modified
RPMI-1640 before centrifugation over Ficoll-Paque
(Amersham Bioscience) at 650 g for 20min. Peripheral
blood mononuclear cells (PBMC) were harvested from the
interface and washed in complete medium. CD41 naı¨ve
T cells were negatively selected from PBMC using Stem-
Sep (StemCell Technologies, Vancouver, Canada) and
separated on Mini-MACS columns (Miltenyi Biotec). The
resultant cells were labelled with 5 mM CFSE (Invitrogen,
Paisley, UK) for 3min at room temperature, and the
reaction was stopped by addition of FCS.
Unfractionated sputum cells, and sputum cells enriched
for or depleted of DC, were used as stimulator cells in an
allogeneic MLR with CFSE-labelled, CD41naı¨ve T cells.
Sputum cells were depleted of DC by cell sorting (gated on
CD11c1lin cells), or by immunomagnetic separation of
langerin1 mononuclear cells. Sorting; sputum cells were
labelled with mAb in PBS containing 0.5% BSA and 2mM
EDTA and sorted in exclusion mode on a FACSCalibur
flow cytometer. Immunomagnetic separation; sputum
cells were centrifuged over Ficoll-Paque (650 g, 20min).
The mononuclear cell-rich interface was labelled with
mouse anti-human langerin-PE (20min, 4 1C), washed in
FACS buffer and then incubated with anti-mouse IgG
microbeads and anti-PE microbeads for 20min on ice
(Miltenyi Biotec). After washing, sputum cells were
depleted of langerin1 cells on Mini-MACS columns
(Miltenyi Biotec). Langerin1 cells were eluted from the
columns as enriched DC.
Enriched blood DC were obtained from the non-adher-
ent fraction of PBMC cultured overnight (37 1C, 5% CO2)
in complete medium at 4106 cells/mL. The non-ad-
herent cells were centrifuged over NycoPrep (10min,
500 g; Axis-shield, Oslo, Norway) and the low-density
cells harvested from the interface. Responder cells were
plated out in 96-well flat-bottom plates at 400 000 cells
per well (cpw). The stimulator cells were added at
8000 cpw. After 5 days of culture, the cells were har-
vested and analysed by flow cytometry. Proliferating cells
were identified by reduction in CFSE staining, and their
number was determined by reference to FlowCount beads
(Beckman Coulter).
Electron microscopy
Sputum cells were immuno-gold labelled against HLA-DR
(L243, BD Biosciences; goat anti-biotin 10 nm gold, BB
International), fixed in 3% glutaraldehyde, embedded in
low gelling temperature agarose (Sigma-Aldrich, Poole,
UK), further fixed in 1% osmium tetroxide and then
stained with 2% uranyl acetate. The cells were dehydrated
using an acetone gradient, embedded in araldite resin and
cured for 18 h at 65 1C. Blocks of cells were cut into
100 nm sections and collected onto copper grids. Sec-
tions were stained with Reynold’s lead citrate and viewed
on a Jeol JEM-1200EX electron microscope (Jeol, Welwyn
Garden City, UK).
Statistics
Statistical analyses were performed using SigmaStat soft-
ware (SPSS, Chicago, IL, USA). Pooled data are expressed
as mean values standard error. t-tests were used to
analyse normally distributed data and Mann–Whitney
rank-sum tests were used to analyse non-normally dis-
tributed data. Two-way analysis of variance was used to
test the endocytosis data. Po 0.05 was considered to be
significant.
Results
Identification of hRTDC in sputum
Cells exhibiting a characteristic DC phenotype (HLA-
DR1lineage /dim) were detected in sputum by flow cyto-
metry (Fig. 1a– R1). The size and granularity of this
population were typical of DC (Fig. 1b– R2; black events).
hRTDC stained predominantly CD11c1 (Fig. 1c– R3), and
their identity was confirmed by immuno-gold electron
microscopy (Fig. 1d).
hRTDC comprised 0.5% of viable sputum cells in
allergen-naı¨ve subjects and there was a tendency towards
elevated proportions of hRTDC in asthmatic sputum cells
(%hRTDC in sputum cells; control, 0.31 0.06%; atopic,
0.36 0.08%; asthmatic, 0.64 0.15%). The total number
of hRTDC obtained by sputum induction was significantly
higher in asthmatic subjects than in healthy control
donors (Fig. 2a; Po 0.05). However, when these values
were corrected for the mass of sputum plugs obtained, this
difference between asthmatic and healthy control donors
was no longer statistically significant (hRTDC number;
24 6103 g 1, n= 12 asthmatic subjects; vs. 42
11103 g 1, n= 12 healthy control donors; P4 0.05),
suggesting that increased airway secretions in asthma
may partially contribute to elevated DC numbers. Putative
plasmacytoid/CD11c DC comprised less than 30% of
hRTDC in each of the subject groups analysed (Fig. 2b),
and sputum from atopic subjects contained a significantly
lower proportion of these cells than was detected in
control subjects (Po 0.05).
hRTDC are potent stimulatory cells
Sputum cells stimulated CD41 naı¨ve T cells to proliferate
with a potency comparable with that of mature blood DC
(Figs 3a and b). The small number of cells available in
sputum prevented DC purification, but partial enrichment/
depletion of hRTDC in sputum cells was used to assay their
c 2007 The Authors
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Fig. 1. Human respiratory-tract dendritic cells (hRTDC) can be identified in induced sputum. HLA-DR1 lineage /dim hRTDC (a – R1) exhibited size and
granularity typical of dendritic cells (b – R2; black events). hRTDC stained predominantly CD11c1 relative to isotype-matched controls (c – R3), and their
identity was confirmed by immuno-gold electron microscopy (d; HLA-DR1 cells exhibiting dendritic morphology, scale bar = 1 mm).
Fig. 2. Higher yields of human respiratory-tract dendritic cells (hRTDC) can be obtained from asthmatic subjects than from healthy controls (a;
Po 0.05). hRTDC were predominantly myeloid/CD11c1 in each of the subject groups analysed, but the proportion of myeloid DC was increased in atopic
sputum when compared with control samples (b; Po 0.05).
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contribution to the stimulatory effects observed. Sputum
cells stimulated significant levels of naı¨ve T cell prolifera-
tion (Fig. 3c). However, partial depletion of myeloid
hRTDC from sputum cells by cell sorting resulted in a
43% reduction in the number of dividing cells detected
(Fig. 3d). A similar reduction was achieved by depletion of
langerin1 cells (putative CD11c1 hRTDC) using column
fractionation. In contrast, enriching for this langerin1
subset increased T cell proliferation 2.5-fold compared
with the unseparated sputum cells stimulus (Fig. 3e).
Enhanced antigen uptake by asthmatic hRTDC
Endocytosis by CD11c1 hRTDC was rapid and sustained,
but asthmatic cells displayed greater activity than their
control or atopic counterparts (Fig. 4; Po 0.001). Plasma-
cytoid DC displayed minimal endocytic activity. In con-
trast, HLA-DR1lin1 monocyte/macrophages (Mo/MF)
displayed 36-fold higher levels of uptake than CD11c1
hRTDC. While Mo/MF from control donors were the most
endocytic of the subject groups (Po 0.001 compared with
asthmatic or atopic Mo/MF), hRTDC from these subjects
were the least effective at antigen uptake.
Elevated expression of CD1c, CD1d, langerin and
maturation markers by CD11c1 hRTDC in asthma
hRTDC were labelled with mAb against various DC sub-
setting and maturation markers. The proportion of posi-
tive cells (%) and the expression level of each marker
(positive intensity/PI ratio) were determined relative to
isotype-matched controls.
Myeloid hRTDC from control subjects expressed only
low levels of co-stimulatory molecules. In contrast,
hRTDC from asthmatics exhibited a phenotype suggestive
of mature DC; they expressed significantly higher levels of
CD80 (PI: 11 2) and CD86 (PI: 14 3) than hRTDC from
controls (PI: 4 1 for CD80; 5 1 for CD86 – Fig. 5a). The
proportion of hRTDC expressing CD80 or CD86 in asth-
matic sputum (50 5% and 71 4%, respectively) was
also significantly higher than was detected in sputum
from control (CD80, 23 6%; CD86, 38 6%) or atopic
subjects (CD80; 24 7%; CD86, 41 10% – Fig. 5b).
Changes in hRTDC phenotype associated with asthma
were not confined to activation markers alone. Asthmatic
CD11c1 hRTDC expressed significantly higher levels of
CD1c, CD1d, CD123 and langerin than equivalent cells
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Fig. 3. Sputum cells are potent stimulators of CD41 naı¨ve T cell proliferation. Sputum cells stimulus (a), blood DC stimulus (b); %, proportion of dividing
cells; bold, absolute numbers. Sputum cells stimulated significant T cell proliferation (c). Depletion of human respiratory-tract dendritic cells (hRTDC)
from sputum cells by cell-sorting (hatched bars), or column separation (solid bars), reduced stimulatory potency (d). hRTDC enrichment increased
stimulation (e).
Fig. 4. Enhanced antigen uptake by myeloid human respiratory-tract
dendritic cells (hRTDC) in asthma. CD11c1 hRTDC demonstrated rapid
and prolonged endocytic activity, with greater efficiency evident in cells
from asthmatic donors (Po 0.001 compared with control or atopic
subjects). CD11c putative hRTDC demonstrated only low levels of
endocytosis. In contrast, sputum macrophages exhibited far greater
levels of endocytic activity than either subset of hRTDC. (MFI; mean
fluorescence intensity).
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from control subjects (Fig. 5a). The proportion of CD11c1
hRTDC expressing CD1c was also significantly increased
(asthmatic, 70 5%; control, 39 7%), and whereas few
CD1d1 cells were detected among the hRTDC population
of control or atopic donors (o 2% stained CD1d1 in these
subject groups), there was a significant number of CD1d1
DC in sputum from asthmatics (11 4% - Fig. 5b).
CD11c ‘hRTDC’ from asthmatic donors include
CD123high cells and display elevated CD40 expression
CD11c ‘hRTDC’ stained only weakly with most of the
reagents tested. It is therefore unclear whether these cells
correspond to conventional CD11c plasmacytoid DC.
Cells expressing high levels of CD123 (a hallmark of
plasmacytoid DC in peripheral blood) were only detected
in sputum from asthmatic donors, and then only in small
numbers. Despite their indeterminate origins, CD40 ex-
pression was both increased on these cells and detected on
a greater proportion of their population in sputum from
asthmatics (Fig. 6).
In a subset of donors, sputum was obtained on two
separate occasions approximately one week apart (n= 3
per allergen-naı¨ve subject group). Surface labelling ana-
lyses were performed on both occasions to assess pheno-
type stability over time. Despite diurnal variability in the
disease symptoms of asthmatic subjects, CD11c1 hRTDC
exhibited a remarkably consistent phenotype in each of
the subject groups analysed (Fig. 7).
Allergen challenge enhances CD1c expression by hRTDC
In a subset of asthmatics, sputum was obtained on three
separate occasions over the course of an allergen chal-
lenge. hRTDC phenotype was analysed pre-challenge, 24 h
post and 72 h post-challenge. The pre-challenge and 24 h
post-challenge analyses are shown in Fig. 8.
hRTDC from asthmatic subjects comprised 0.5% of
viable sputum cells before allergen administration, but by
24 h post-challenge the proportion of hRTDC had in-
creased between 1.6-and 9.5-fold. The proportion of
hRTDC expressing CD11c also increased markedly follow-
ing allergen inhalation (54 10% in allergen-naı¨ve
sputum, 82 4% in post-challenge samples, data not
shown).
Expression of CD1c by asthmatic myeloid hRTDC was
increased between 3- and 9-fold within 24 h of allergen
administration (Po 0.05; Fig. 8). In two of three donors,
Fig. 5. Asthmatic CD11c1 human respiratory-tract dendritic cells
(hRTDC) exhibit a CD11 mature phenotype. The staining intensity (a)
and proportion of positive cells (b) labelled with specific mAb were
measured relative to isotype-matched controls. Bars indicate mean
values1standard error. Po 0.05 vs. control, Po 0.01 vs. control,
P40.001 vs. control,1Po 0.05 vs. atopic,11Po 0.01 vs. atopic,
111P40.001 vs. atopic. Atopic asthmatic, n= 12; non-atopic control,
n=12; atopic non-asthmatic, n=6.
Fig. 6. CD11c human respiratory-tract dendritic cells (hRTDC) display
increased CD40 expression in asthma. The staining intensity (a) and
proportion of positive cells (b) labelled with specific mAb were measured
relative to isotype-matched controls. Bars indicate mean values1stan-
dard error. Po 0.05 vs. control. Atopic asthmatic, n= 12; non-atopic
control, n= 12; atopic non-asthmatic, n= 6.
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CD1c expression declined to an intermediate level at 72 h
post-challenge (between 1.9- and 3.6-fold of allergen-
naı¨ve baseline) but in the third subject, CD1c expression
was increased yet further (19-fold of allergen-naı¨ve
baseline, data not shown). Langerin expression by asth-
matic myeloid hRTDC was also augmented following
allergen inhalation; 24 h post-challenge, levels of staining
had increased to more than double those observed on
autologous, allergen-naı¨ve cells. CD40 and CD86 expres-
sion by CD11c1 hRTDC from asthmatic subjects were
also enhanced upon allergen challenge – the intensity of
staining for these co-stimulatory molecules approxi-
mately doubled on pre-challenge levels. In addition,
allergen challenge increased the proportion of CD11c
CD123high hRTDC detected in asthmatic sputum (Fig. 8),
although detected no other marked effects upon the
CD11c population were detected.
Discussion
hRTDC were successfully identified in induced sputum
using multi-colour flow cytometry. This non-invasive
approach revealed that hRTDC activation, increased capa-
city for antigen uptake and enhanced expression of CD1c
and CD1d are specifically associated with atopic asthma.
Fig. 7. CD11c1 human respiratory-tract dendritic cells (hRTDC) exhibit a stable phenotype. The staining intensity of hRTDC labelled with specific mAb
was measured on two separate occasions approximately one week apart (relative to isotype-matched controls) in three individual subjects per allergen-
naı¨ve subject group. The phenotype of atopic CD11c1 hRTDC was indistinguishable from the control phenotype by this analysis. ND=not determined.
Fig. 8. Asthmatic human respiratory-tract dendritic cell (hRTDC) phenotype is modulated upon allergen challenge. Asthmatic hRTDC were analysed
pre- and 24 h–post-allergen challenge; subject 1, ; subject 2, m; subject 3, ’. Solid symbols = expression level of respective markers on myeloid
hRTDC relative to isotype-matched controls. Open symbols = proportion of CD1231 plasmacytoid DC detected. Po 0.05 vs. allergen-naı¨ve phenotype.
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hRTDC displayed a typical DC phenotype, morphology
and functional characteristics. Sputum cells stimulated
the proliferation of CD41 naı¨ve T cells with a potency
comparable with that of mature blood DC. Although
purification was prohibited by low cell numbers, enrich-
ment/depletion of DC in sputum cells identified hRTDC as
the major stimulatory cells present. Consistent with these
data, CD1a1 DC from bronchoalveolar lavage fluid are
reported to be potent accessory cells [20], whereas alveo-
lar macrophages are defective in this role [21].
hRTDC comprised o 0.4% of viable sputum cells from
control or atopic subjects, but 0.6% of viable sputum
cells from asthmatic subjects. Small numbers of
CD123highCD11c hRTDC were consistently detected, but
only in asthmatic sputum. Moreover, allergen inhalation
increased the number of CD123highCD11c hRTDC ob-
served in asthmatic sputum, alongside increases in the
number of myeloid hRTDC detected – both in direct
correlation with airflow obstruction. These data suggest
recruitment of circulating DC precursors to the inflamed
asthmatic mucosa [14], and support a role for CD11c1
RTDC as pro-inflammatory mediators in allergic airway
disease [11]. In a murine model of asthma, plasmacytoid
DC mediate allergen tolerance in the thoracic lymph nodes
by inhibiting the pro-inflammatory effects of myeloid
RTDC [22]. However, it is unclear whether the
CD123highCD11c hRTDC described by the current study
correspond to the ‘tolerogenic’ murine population reported
by other investigators, or whether these cells are similarly
capable of suppressing inflammation in the human lung.
The conventional model of DC maturation associates
enhanced stimulatory potency with decreased endocytic
capacity [3]. However, despite the increased maturity of
myeloid hRTDC in asthma, these cells were more endocy-
tic than their control or atopic counterparts and expressed
high levels of langerin, a receptor for antigen internaliza-
tion [23]. Allergen challenge further increased langerin
expression by asthmatic myeloid hRTDC, despite a con-
comitant increase in the expression of maturation mar-
kers. These data indicate that the regulation of stimulatory
capacity and antigen acquisition can be uncoupled in the
airways. In asthma, this dichotomy of function may
permit continuous sampling and presentation of respira-
tory antigen by mature, stimulatory hRTDC. Indeed, the
reduced endocytic activity displayed by sputum Mo/MF
in asthma could contribute to this effect by allowing
respiratory antigen to accumulate in the airways and
increase hRTDC exposure to maturational stimuli.
hRTDC expression of langerin, CD1c and CD1d was
significantly increased in asthma. CD1c1 DC have been
described at sites of airway inflammation by other inves-
tigators [6, 14], but our data extend these findings in
several ways. Firstly, we have been able to quantify
asthma-related changes in the hRTDC phenotype at the
single-cell level, revealing that local up-regulation of
CD1c expression, as well as enhanced recruitment, can
underlie allergen-driven increases in CD1c1 hRTDC in the
asthmatic lung [14]. Secondly, we observed heterogeneity
within the hRTDC population; both CD1c1 and CD1c DC
subsets displayed evidence of phenotypic modulation in
asthma that was independent of changes in population
size. Other investigators have previously identified potent
stimulatory subsets of CD1a1, CD1c1 and BDCA-31 DC
in human lung tissue, as well as a trace population of
plasmacytoid DC that displayed only low levels of
HLA-DR and co-stimulatory molecules [24]. The data
presented in the current study are consistent with these
findings, but extend the analysis of hRTDC populations to
include quantitative determination of their phenotypic
and endocytic modulation in asthmatic disease. It is
unlikely that the DC populations we identified in sputum
are a contaminating population derived from the blood
since they lack the major subset of CD11c DC (BDCA-21
BDCA-41 CD123hi) that comprise approximately half of
circulating blood DC [25]. Although the anatomical origin
of DC obtained by sputum induction remains to be
definitively identified, it is likely that many of these cells
are derived from the tissues of the conducting airways as
analysis using radiolabelled bolus delivery suggests that
this is the major site sampled by the induced sputum
technique [26]. The similarities between the data pre-
sented here and those reported by Demedts et al. [24], in
their study of biopsy-derived DC, and more specifically
the presence of CD1a1 DC in our samples (cells that are
present in the epithelium of the conducting airways but
not the lung parenchyma), strongly support the concept
that the mucosa of the conducting airways contributes DC
to the populations we have analysed. The relative con-
tributions of lumenal, epithelial and submucosal DC
populations are harder to determine and may be influ-
enced by the ability of hypertonic saline to increase
sampling of the deeper tissues.
While up-regulation of co-stimulatory molecules could
simply be indicative of inflammatory activity, this does
not provide an adequate explanation for changes in CD1c,
CD1d and langerin expression by CD11c1 hRTDC. Indeed,
langerin can mediate the uptake of exogenous lipid
antigen for CD1 presentation by DC [27], and the activa-
tion of ‘unconventional’ T cells by this route could play a
critical role in asthma pathogenesis [8].
gd T cells and CD4CD8 ab T cells can be activated by
respiratory antigen presented in the context of CD1 [28],
and CD1d-restricted NKT cells could play a critical role in
asthmatic disease [10], but it is unclear whether DC
presentation of CD1-restricted antigens is modulated in
the asthmatic respiratory tract. CD1 molecules mediate the
presentation of ubiquitous environmental antigens of
both microbial and self origin [29, 30]. Cross-talk between
DC and CD1-restricted T cells is bi-directional and can
induce maturation of CD11 immature, myeloid DC that
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present appropriate self-antigen [6, 31]. There is also
evidence that RTDC maturation can be induced by inter-
action with T cell subsets in the airway mucosa [32]. It is
possible then that enhanced recognition of CD1 : self-
antigen complexes in the pulmonary tissues leads to
inappropriate hRTDC maturation by innate lymphocytes
such as NKT cells [10]. Increased expression of co-stimu-
latory molecules could subsequently enhance hRTDC
presentation of MHC/CD1–antigen complexes. Similar
events have already been described in vitro; maturation
of CD1c1 myeloid DC – an abundant population in
asthmatic sputum – can be induced by cell : cell contact
with CD1c-restricted gd T cells [6]. The resultant mature,
CD1c1 DC are endocytic, can present novel protein anti-
gen and are potent stimulators of naı¨ve T cells, features
identified as characterizing asthmatic, myeloid hRTDC in
the current study.
Vd11 gd T cells constitute the main tissue subset of gd
T cells and recognize CD1c in the absence of foreign
antigen [6]. These cells are predominantly auto-reactive
and may facilitate rapid immune activation in the periph-
eral tissues. Vd11 gd T cells are enriched in the lungs of
asthma patients following disease exacerbations and pro-
duce TNF-a upon mitogen stimulation [33]. gd T cells play
an important role in pulmonary homeostasis [34], and can
produce TNF-a to induce maturation of CD1c1 myeloid
DC [6, 35]. TNF-a has been implicated in numerous
models of DC maturation by innate lymphocytes [36],
and may depend upon up-regulated ICAM-1 expression
and enhanced lymphocyte clustering [35]. It is intriguing
therefore that TNF-a production is increased in the asth-
matic lung [37], and that allergen exposure induces
ICAM-1 up-regulation and in situ maturation of pulmon-
ary DC in a murine model of asthma [32, 38].
Pollen contains bioactive lipids that can modulate DC
function [39]. Pollen-derived lipids can also be presented
by CD11 DC in vitro [9], and are attractive candidates for
CD1 presentation by hRTDC in the airways. In the current
study, allergen inhalation enhanced CD1c expression by
asthmatic myeloid hRTDC between 3- and 19-fold vs. the
allergen-naı¨ve phenotype. It is possible then that regula-
tion of CD1 expression by hRTDC plays a critical role in
allergic asthma, influencing DC maturation by innate
lymphocytes and presentation of pollen-lipid antigens.
Moreover, it is tempting to speculate that the ability of
mycobacteria to inhibit CD1 expression by DC [40] may
underpin the protection against asthma conferred by
childhood exposure to mycobacterial products [41].
Airway DC have been extensively studied in animal
systems, but parallel work in the human system has lagged
behind. The heterogeneity of hRTDC, when coupled with
the diversity of methods, cell sources and animal models
used to study these cells, probably accounts for the
discrepancies observed in earlier data. The novel approach
used by the current study limits the effects of ex vivo
manipulation on RTDC phenotype [15, 16], and avoids
contamination with blood and peripheral lung DC –
populations that are distinct from mucosal hRTDC [32, 42].
Currently, we can only speculate upon the possible
reasons for the differential phenotype and function
exhibited by myeloid hRTDC in asthma, but the
data reported here are striking and may prove critical
in asthma pathogenesis. Further definition of aberrant
hRTDC function in allergic asthma will further our under-
standing of immune regulation in the human airway and
may lead to the identification of novel targets for ther-
apeutic interventions.
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